CONSHOHOCKEN, PA -- (Marketwire) -- 09/30/10 -- NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jerry McLaughlin, Vice President of Commercial Operations, will present a brief company overview at the Safeguard Scientifics, Inc. (NYSE: SFE) Investor Day 2010 event on Tuesday, October 5, 2010. The investor day is being held at The Yale Club in New York.

A live audio webcast of the presentation will be available at www.safeguard.com/InvestorDay2010. Please log on approximately 10 minutes prior to the scheduled start time.

About NuPathe

NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief™ technology.

In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit NuPathe's website at www.nupathe.com.